<DOC>
	<DOCNO>NCT01445119</DOCNO>
	<brief_summary>This study evaluate safety effectiveness Enzastaurin , experimental drug may prevent growth tumor vessel , combination Carboplatin , patient glioma , type brain tumor . Carboplatin use treat many kind cancer , though recurrent glioma . Tumor growth involve new cancer cell formation accumulation , require blood supply . Research show brain tumor cell produce substance stimulate new blood vessel formation . This study look whether combination drug stop process . Patients age 18 old recur glioma , pregnant breast feeding , serious disease may eligible study . About 96 patient participate 1 year . They physical examination , give blood urine sample analysis , undergo magnetic resonance imaging ( MRI ) compute tomography ( CT ) scan regard tumor growth , perhaps electrocardiogram . Patients may also undergo dynamic MRI spectroscopy PET scan ( positron emission tomography ) , distinguish live tumor die one . Researchers study patient take certain type antiseizure medicine patient take antiseizure medicine may change way body handle drug Enzastaurin . There two group participant , 16 48 . Group A take enzyme-inducing antiseizure drug , Group B take drug . In Groups A B four dose level , 4 to12 patient level . Patients ' doctor tell group belong much Enzastaurin Carboplatin take . Treatment consist Enzastaurin every day 5 week Cycle 1 4 week begin Cycle 2 ( 4-week period cycle ) . Patients take Enzastaurin within 30 minute meal . History , physical , neurological examination repeat end Cycle 1 every 4 week . Patients repeat head MRI CT scan cycle . If tolerate drug without serious side effect tumor grow , may continue another cycle Enzastaurin , take tablet every day , Carboplatin infuse Day 8 Cycle 1 Day 1 additional cycle . Routine lab test do regularly . Patients continue 4-week cycle treatment long serious side effect sign tumor growth . Side effect Enzastaurin may fatigue , constipation , cough , nausea . In men , may decrease sperm count . Carboplatin lead low count blood cell platelet , may also allergic reaction . Vomiting likely side effect . At injection site , may redness , swell , pain . This study may may direct benefit participant . However , information gain may help sponsor study , Eli Lilly Company , may help patient future glioma .</brief_summary>
	<brief_title>A Phase I Trial Enzastaurin ( LY317615 ) Combination With Carboplatin Adults With Recurrent Gliomas</brief_title>
	<detailed_description>Background : - Enzastaurin , macrocyclic bisindolylmaleimide disrupts intrinsic phosphotransferase activity conventional novel PKC isoforms via interaction ATP binding site , display selectivity inhibit isoforms . Preclinical study demonstrate potent anti-angiogenic activity enzastaurin study normal volunteer solid tumor patient demonstrate drug well tolerated dos achieve biologically active serum concentration . - Carboplatin show activity monotherapy treatment recurrent malignant glioma adult preclinical data generate laboratory demonstrates additive anti-glioma activity enzastaurin . The safety profile carboplatin preclinical clinical data support use combination enzastaurin patient malignant glioma . Objective : -To establish maximally tolerate dose enzastaurin combination carboplatin patient refractory primary brain tumor enzyme-inducing anti-epileptic drug ( nEIAED ) patient EIAEDs . Eligibility : -Patients histologically prove malignant glioma eligible study . Design : -Patients stratify two group base anti-epileptic medication ( nEIAEDs = Group A , EIAED = Group B ) Group A : Each cycle therapy consist enzastaurin administer daily 4 week breaks cycle . All patient receive 7-day lead-in treatment period ( Cycle 1 ) consist load dose oral enzastaurin Day 1 1125mg , follow enzastaurin administer daily 500mg 6 additional day order achieve steady state pharmacokinetics enzastaurin . The first dose carboplatin administer Day 8 Cycle 1 , consist 35 day . Following lead-in treatment period , first combination cycle enzastaurin carboplatin ( Cycle 2 ) commence 28-day cycle . Within combination cycle , enzastaurin orally administer 500mg daily Days 1 28 carboplatin administer intravenous infusion approximately 30 minute Day 1 every 28 day . The carboplatin dose 3 AUC dose level one . For dose level 2 , 3 , 4 , carboplatin dose 4 , 5 6 AUC , respectively . Group B : Each cycle therapy consist enzastaurin administer daily 4 week breaks cycle . All patient receive 7-day lead-in treatment period ( Cycle 1 ) consist load dose oral enzastaurin Day 1 1125mg , follow enzastaurin administer daily 875mg 6 additional day order achieve steady state pharmacokinetics enzastaurin . The first dose carboplatin administer Day 8 Cycle 1 , consist 35 day . Following lead-in treatment period , first combination cycle enzastaurin carboplatin ( Cycle 2 ) commence 28-day cycle . Within combination cycle , enzastaurin orally administer daily Days 1 28 875mg carboplatin administer intravenous infusion approximately 30 minute Day 1 every 28 day . The carboplatin dose 3 AUC dose level one . For dose level 2 , 3 , 4 , carboplatin dose 4 , 5 6 AUC , respectively . National Cancer Institute ( NCI ) register trial Eli Lilly sponsor . NCI update record . In June 2013 , NCI transfer trial Lilly 's clinicaltrials.gov account Lilly update record trial status , study start date , completion date . This trial applicable trial Food Drug Administration Amendments Act 2007 ( FDAAA ) .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients histologically prove malignant glioma progressive disease follow standard treatment eligible protocol . Malignant glioma include glioblastoma multiforme ( GBM ) , anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic mixed oligoastrocytoma ( AMO ) , malignant glioma NOS ( otherwise specify ) . Additionally , patient primitive neuroectodermal tumor ( PNETs ) central nervous system , progressive lowgrade glioma radiographically diagnose brain stem glioma eligible . 2 . Patients must unequivocal evidence tumor progression MRI CT scan . This scan perform within 14 day prior registration steroid dosage stable least 5 day . If steroid dose increase date image registration new baseline MR/CT require . The type scan , is. , MRI CT must use throughout period protocol treatment tumor measurement . 3 . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : A . They recover effect surgery . B . Residual disease follow resection recurrent tumor mandate eligibility study . To best assess extent residual disease postoperatively , CT/ MRI do : later 96 hour immediate postoperative period least 4 week postoperatively , within 14 day registration , steroid dosage stable least 5 day . If 96 hour scan 14 day registration , scan need repeat . If steroid dose increase date imaging registration , new baseline MRI/CT require stable steroid dosage least 5 day . 4 . Patients must fail prior radiation therapy must interval great equal 4 week completion radiation therapy study entry . 5 . All patient previously designate LAR ( Legally Authorized Representative ) ( patient deem treat physician cognitively impaired questionably impaired way ability patient give inform consent questionable ) must sign informed consent indicate aware investigational nature study . Patients register prior start study . 6 . Patients must great equal 18 year old , life expectancy great 8 week . 7 . Patients must Karnofsky performance status great equal 60 . 8 . Patients must recover toxic effect prior therapy : 2 week noncytotoxic investigational agent , 4 week prior cytotoxic therapy , two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , example. , interferon , tamoxifen , thalidomide , cisretinoic acid , etc . ( radiosensitizer count ) . Any question relate definition noncytotoxic agent direct Study Chair . 9 . Patients must adequate bone marrow function ( WBC great equal 3,000/microl , ANC great equal 1,500/mm ( 3 ) , platelet count great equal 100,000/mm ( 3 ) , hemoglobin great equal 10 gm/dl ) , adequate liver function ( SGOT bilirubin less equal 2 time ULN ) , adequate renal function ( creatinine less equal 1.5 mg/dL and/or creatinine clearance great equal 60 cc/min ) start therapy . These test must perform within 14 day prior registration . Eligibility level hemoglobin may reach transfusion . 10 . Patients must significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy . 11 . This study design include woman minority , design measure difference intervention effect . Males female recruit preference gender . No exclusion study base race . 12 . Patients must practice adequate contraception . 13 . Prior treatment enzyme induce antiepileptic drug must discontinue least 14 day prior study entry Group A patient . EXCLUSION CRITERIA : 1 . Patients , view treat physician , significant active cardiac , hepatic , renal disease ineligible . 2 . No concurrent use standard chemotherapeutics investigative agent . 3 . Prior treatment platinumbased therapy . 4 . Patients know allergic response mannitol . 5 . Patients know active malignancy malignant glioma ( except nonmelanoma skin cancer carcinoma insitu cervix ) . 6 . Patients active infection require IV antibiotic . 7 . Patients pregnant breast feed . 8 . Patients disease obscure toxicity dangerously alter drug metabolism . 9 . QTc Bazett 's correction unmeasurable , great equal 460 msec screen ECG . If patient QTc great equal 460 msec screen ECG , second screen ECG may repeat least 24 hour apart . The average QTc 2 screen ECGs must less 460 msec order patient eligible study . 10 . EKG demonstrate clinically significant arrythmia ( multifocal premature ventricular contraction [ PVC ] , bigeminy , trigeminy , ventricular tachycardia , bradycardia ) symptomatic require treatment ( CTCAE Grade 3 ) , asymptomatic sustain ventricular tachycardia . 11 . Patients baseline EKGs suggestive past present cardiac ischemia eligible unless appropriate ( defined P.I . trial ) negative cardiac work ( , echocardiogram , stress test ) . 12 . Patients may systemic anticoagulant ( , heparin , warfarin , small heparin fragment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Brain</keyword>
	<keyword>Tumor</keyword>
	<keyword>Radiation</keyword>
	<keyword>Antiangiogenesis</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Glioma</keyword>
</DOC>